A. Chalmers

492 total citations
29 papers, 321 citations indexed

About

A. Chalmers is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, A. Chalmers has authored 29 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in A. Chalmers's work include Chronic Lymphocytic Leukemia Research (5 papers), Protein Degradation and Inhibitors (5 papers) and Sarcoma Diagnosis and Treatment (5 papers). A. Chalmers is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Protein Degradation and Inhibitors (5 papers) and Sarcoma Diagnosis and Treatment (5 papers). A. Chalmers collaborates with scholars based in United States, United Kingdom and France. A. Chalmers's co-authors include Wallace Akerley, Jamile M. Shammo, Shiven B. Patel, Christopher Parrish, Jim Cavet, John A. Snowden, Julia Brown, T. C. M. Morris, Jamie Cavenagh and David A. Cairns and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

A. Chalmers

28 papers receiving 313 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Chalmers United States	9	176	120	98	97	57	29	321
Praveen Ramakrishnan Geethakumari United States	9	183 1.0×	41 0.3×	50 0.5×	65 0.7×	34 0.6×	51	304
Laurence Reilly United States	5	198 1.1×	302 2.5×	97 1.0×	93 1.0×	239 4.2×	8	543
Mahran Shoukier United States	9	94 0.5×	115 1.0×	78 0.8×	32 0.3×	71 1.2×	23	249
Richard Pilot United States	5	164 0.9×	177 1.5×	64 0.7×	47 0.5×	68 1.2×	10	368
Yong Mun United States	11	313 1.8×	31 0.3×	132 1.3×	115 1.2×	54 0.9×	43	464
Lok Lam Ngai Netherlands	9	116 0.7×	98 0.8×	54 0.6×	178 1.8×	24 0.4×	17	370
L. Andres Sirulnik United States	10	173 1.0×	96 0.8×	106 1.1×	43 0.4×	33 0.6×	17	297
Michelle Purdom United States	7	129 0.7×	29 0.2×	107 1.1×	75 0.8×	71 1.2×	13	293
Cindi Bedell United States	9	212 1.2×	36 0.3×	174 1.8×	65 0.7×	40 0.7×	14	401
Claudia A.M. Stege Netherlands	8	110 0.6×	126 1.1×	95 1.0×	36 0.4×	19 0.3×	15	239

Countries citing papers authored by A. Chalmers

Since Specialization

Citations

This map shows the geographic impact of A. Chalmers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Chalmers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Chalmers more than expected).

Fields of papers citing papers by A. Chalmers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Chalmers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Chalmers. The network helps show where A. Chalmers may publish in the future.

Co-authorship network of co-authors of A. Chalmers

This figure shows the co-authorship network connecting the top 25 collaborators of A. Chalmers. A scholar is included among the top collaborators of A. Chalmers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Chalmers. A. Chalmers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schöffski, Patrick, Robin L. Jones, Mark Agulnik, et al.. (2024). Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report. ESMO Open. 9(7). 103487–103487. 1 indexed citations

D’Angelo, Sandra P., Andrew Furness, Fiona Thistlethwaite, et al.. (2024). Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial.. Journal of Clinical Oncology. 42(16_suppl). 2500–2500. 9 indexed citations

Wen, Ping, Jan Drappatz, R. Jena, et al.. (2024). Safety and Preliminary Efficacy of AZD1390 + Radiation Therapy for Glioblastoma. International Journal of Radiation Oncology*Biology*Physics. 120(2). S119–S120. 4 indexed citations

Ingham, Matthew, Li Chen, Biswajit Das, et al.. (2024). Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS).. Journal of Clinical Oncology. 42(16_suppl). 11526–11526. 3 indexed citations

Tap, William D., John A. Charlson, Lara E. Davis, et al.. (2024). 53O Results from a phase II part I trial of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in patients with advanced refractory sarcoma. ESMO Open. 9. 102443–102443. 5 indexed citations

Puri, Sonam, Rachna Malani, A. Chalmers, et al.. (2023). Keeping a track on leptomeningeal disease in non–small cell lung cancer: A single-institution experience with CNSideTM. Neuro-Oncology Advances. 6(1). vdad150–vdad150. 3 indexed citations

Lee, Shing M., Mihaela Druta, Anthony P. Conley, et al.. (2023). ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.. Journal of Clinical Oncology. 41(16_suppl). 11531–11531. 1 indexed citations

Patel, Shiven B., Benjamin Haaland, Dominik Ose, et al.. (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. JCO Oncology Practice. 16(4). e313–e323. 42 indexed citations

Chalmers, A., et al.. (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Targeted Oncology. 14(4). 417–421. 40 indexed citations

10.

Chalmers, A., et al.. (2018). Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. The Oncologist. 24(7). 963–972. 19 indexed citations

11.

Dimou, Anastasios, Terry L. Ng, A. Chalmers, et al.. (2018). OA12.06 Mutational Landscape of BRAF V600E Positive Lung Cancer Patients Following BRAF Directed Therapy Failure. Journal of Thoracic Oncology. 13(10). S349–S349.

12.

Patel, Shiven B., Wallace Akerley, Dominik Ose, et al.. (2018). Prognostic value of patient-reported outcomes (PROs) in advanced cancer.. Journal of Clinical Oncology. 36(30_suppl). 8–8. 1 indexed citations

13.

Chalmers, A., Leif Jensen, & Wallace Akerley. (2017). Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report. Lung Cancer. 114. 68–69. 10 indexed citations

14.

McDonald, Fiona, Alastair Greystoke, Stephen L. Brown, et al.. (2017). EP-1228: UK NCRI CTRad consensus on drug and radiotherapy combination platform studies in NSCLC. Radiotherapy and Oncology. 123. S662–S663. 1 indexed citations

15.

Parrish, Christopher, Curly Morris, Cathy Williams, et al.. (2016). Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. Biology of Blood and Marrow Transplantation. 22(6). 1009–1016. 6 indexed citations

16.

Shammo, Jamile M. & A. Chalmers. (2016). Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. Therapeutics and Clinical Risk Management. 12. 201–201. 21 indexed citations

17.

Rawstron, Andy C., Dena Howard, Lucy McParland, et al.. (2016). Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up. Blood. 128(22). 3226–3226. 8 indexed citations

18.

Cook, Gordon, Cathy Williams, Julia Brown, et al.. (2014). High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. The Lancet Oncology. 15(8). 874–885. 95 indexed citations

19.

Chalmers, A.. (2012). 350 OVERCOMING RESISTANCE OF GLIOBLASTOMA TO CONVENTIONAL CYTOTOXIC THERAPIES BY THE ADDITION OF PARP INHIBITORS. Radiotherapy and Oncology. 102. S183–S183. 2 indexed citations

20.

Boyd, Sally, et al.. (2001). Beyond School: Final Year School Students' Experiences of the Transition to Tertiary Study or Employment.. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact